Quintiles has scooped up a provider of genomic testing and analysis as the global pharma services company beefs up its internal capabilities to support the development of personalized drugs.
Merck has inked a deal with PatientsLikeMe, a provider of online patient communities, to gain insights into challenges of living with psoriasis. And the U.S. drug giant plans to apply the knowledge for clinical research and understanding the autoimmune disease from a patient point of view.
The deal gives the U.S. regulator access to the company's I2E technology, which its labs plan to use to mine text from publications and drug labels.
Eric Schadt made a high-profile move last year to head the Mount Sinai School of Medicine's new Institute for Genomics and Multiscale Biology in New York, and the life sciences maverick has spent his first year on the job building a crack team of bio data and computing aces, engaging experts inside and outside of medicine to solve healthcare problems and forming collaborations with masters of taming massive amounts of data.
Sanofi wants to know its target audience of consumers with diabetes, and the French drug giant has found that social media in their multiple incarnations serve as useful windows into the lives of people with the disease. At stake is one of the fastest-growing markets in the pharma game, one of vital strategic importance to Sanofi ($SNY).
Before the end of the year, medical research and patient data will be just a click away for British scientists with the impending launch of four ehealth research centers across the U.K.
BioClinica is increasing investment in infrastructure to handle an expected surge in demand for its eClinical suite. The investment--which will total $9 million in 2012--comes as BioClinica service revenues hit record highs in the second quarter.
Charles River increased global IT spending by 20% in the second quarter as it continued investing to win strategic deals. And the policy is paying dividends, with execs calling IT a driver of market share gains in the quarter.
Scientific software maker Accelrys grew revenue to $41.6 million in the most recent quarter and kept pushing to become a platform for drugmakers and other R&D operations to manage and share lab data.
Bayer has entered the blogosphere with a U.K. blog about diabetes, for which the healthcare giant sells blood glucose monitors and other products. Launched in June, the blog has produced an infrequent stream of posts on a range of diabetes-related topics from a stable of writers with diverse backgrounds in healthcare and extreme sports.
Accenture agreed to acquire Octagon Research Solutions, boosting its ability to aid life sciences clients with managing clinical data and making submissions to regulators.
London-based drug giant AstraZeneca has headlined a group of early users of Boston-based startup Knode's search engine of sorts for finding life sciences experts and their digital content, becoming the first Big Pharma revealed as an adopter of the web-based software.
Medidata Solutions ($MDSO) gave investors in the clinical trial software company something to celebrate Tuesday--a contract worth more than $100 million, making it the largest deal in the company's history.
Generic drugs took a huge bite out of pharma giant AstraZeneca's ($AZN) sales in the most recent quarter, yet the London-based company also expects to take a 1% haircut off its annual revenue this year because of problems with its new IT system at a plant in Södartälje, Sweden. The IT issues, which the company didn't describe in detail, took a toll on production at the facility.
At AstraZeneca ($AZN), scientists can search a virtual research exchange to shop for services from contract research groups in a similar fashion to browsing an online marketplace such as Amazon.com ($AMZN).
AstraZeneca ($AZN) has plenty to learn from clinical trials that ended in failure, and the company has turned to many different new computer technologies to streamline its R&D efforts and boost efficiency in drug development. A company executive talks about these efforts in a wide-ranging interview with Bio-IT World.
Supercomputers and models aided researchers in understanding enzymes that metabolize cocaine, potentially before molecules of the addictive drug hit the brain. And the use of models has helped researchers push ahead to develop treatments for cocaine overdose and abuse.
As promised, Illumina ($ILMN) has hit the market with a cloud computing system for genomics data, building off its leadership in DNA sequencing to grab a piece of the growing bioinformatics side of the genomics game.
As interpreting DNA sequencing data becomes a focus in biotech research, Complete Genomics ($GNOM) and Ingenuity Systems plan to roll up their technologies to provide a more complete combined service to sequencing customers.